Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L)

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

(2022) Jonathan D Schoenfeld et al.   LANCET ONCOLOGY

Pemetrexed Plus Platinum With or Without Pembrolizumab in Patients With Previously Untreated Metastatic Nonsquamous NSCLC: Protocol-Specified Final Analysis From KEYNOTE-189

(2021) D. Rodríguez-Abreu et al.   ANNALS OF ONCOLOGY

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

(2021) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

(2021) Daniel J. Olson et al.   JOURNAL OF CLINICAL ONCOLOGY

FP13.04 KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLC

(2021) B.C. Cho et al.   Journal of Thoracic Oncology

Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study

(2021) Luana Calabrò et al.   Lancet Respiratory Medicine

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small cell lung cancer

(2021) A.J. Schoenfeld et al.   ANNALS OF ONCOLOGY

A Phase IB study of Durvalumab with or without Tremelimumab and Platinum-Doublet Chemotherapy in Advanced Solid Tumours: Canadian Cancer Trials Group Study IND226

(2020) Rosalyn A. Juergens et al.   LUNG CANCER

Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer

(2020) Charles Dolladille et al.   JAMA Oncology

Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial

(2020) Nathalie Baize et al.   LANCET ONCOLOGY

Heterogeneous expression of programmed death receptor-ligand 1 on circulating tumor cells in patients with lung cancer

(2019) Yasuhiro Koh et al.   Clinical Lung Cancer

Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies

(2019) KOHEI FUJITA et al.   ANTICANCER RESEARCH

Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer

(2019) Eiki Ichihara et al.   LUNG CANCER

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

(2019) Audrey Simonaggio et al.   JAMA Oncology

Current opinions in immune checkpoint inhibitors rechallenge in solid cancers

(2019) E. Gobbini et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma

(2017) Suzanne George et al.   IMMUNITY

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer

(2016) Valsamo Anagnostou et al.   Cancer Discovery

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

(2015) Stefani Spranger et al.   NATURE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE